Key facts
- Ryse Health’s last known valuation is $16.0M (Apr 2025).
- It has raised $16.6M across 2 recorded rounds; the latest was Early Stage VC ($9.8M) in Dec 2022.
- Notable investors include Carefirst of Maryland, Blue Shield of California, Healthworx, John Wray, Kelly Close — 9 tracked in total.
- Ryse Health has filed 2 Form Ds with the SEC since 2021, most recently Jan 2023 ($9.8M sold to 27 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Ryse Health
Funding rounds
2 roundsAbout Ryse Health
Operator of an online care platform intended to help individuals and families with type two diabetes and cardiometabolic health. The company's platform provides therapeutic support and technology, day-to-day coaching, a virtual care model, and analytics related to diabetes, enabling patients to have easy in-person and virtual access to an endocrinologist and full care team.
- Sector
- Healthcare
- HQ
- Arlington, VA, United States
- Founded
- 2020
- Employees
- 16
- Website
- rysehealth.com/
- Ownership
- Privately Held (backing)
Ryse Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ryse Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ryse Health in its N-PORT filings yet. We sweep new filings monthly.